Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 18, 2024 06:27 ET | Source: Research and Markets

Acute Respiratory Distress Syndrome Analysis Report 2024: A $2.36 Billion Market by 2032 from $1.23 Billion in 2023

Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome Market Report by Type, End User, Regions and Company Analysis 2024-2032" report has been added to ...
September 28, 2021 11:09 ET | Source: The Insight Partners

Acute Lung Injury Market Size to Outstrip $741.98Mn by 2028 Growth Projections at 4.7% CAGR During 2021 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com

New York, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Acute Lung Injury Market: Key InsightsAccording to our new research study on "Acute Lung Injury Market to 2028 – Global Analysis and Forecast – by...
May 17, 2021 07:00 ET | Source: Angion Biomedica Corp.

Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results

UNIONDALE, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
March 30, 2021 16:05 ET | Source: Angion Biomedica Corp.

Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

UNIONDALE, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
March 25, 2021 00:05 ET | Source: Angion Biomedica Corp.

Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia

UNIONDALE, N.Y., March 25, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
July 19, 2011 10:31 ET | Source: P2D Bioscience

P2D Bioscience Receives NIH Funding to Develop Drugs for Lung Disease

CINCINNATI, OH and MUMBAI, INDIA--(Marketwire - Jul 19, 2011) - P2D Bioscience (P2D, Inc.), a pharmaceutical development company, announced today that the company has received a $320,000 grant from...